Purpose Tacrolimus pharmacokinetics and calcineurin activity in peripheral blood mononuclear cells (PBMCs) were investigated in adult patients undergoing primary living-donor liver transplantation (LDLT) in order to clarify the significance of monitoring the tacrolimus blood trough concentration during the early post-transplantation period.
Introduction
Tacrolimus, a calcineurin (CN) inhibitor, is widely used to prevent acute rejections after liver transplantation. In this context, therapeutic drug monitoring (TDM) of this drug is recommended to adjust dosages because of its narrow therapeutic index [1, 2] . Despite the large inter-individual variation in tacrolimus pharmacokinetics, the area under the concentration-time curve (AUC) versus the trough blood concentration (C 0 ) has a nearly linear relationship [3, 4] , and the C 0 of tacrolimus is usually monitored in patients receiving this drug. However, in some cases of renal transplantation, the correlation between C 0 and the AUC of tacrolimus is not adequate [5] . With cyclosporine, another CN inhibitor, the C 0 does not correlate well with systemic drug exposure, and blood concentrations at 2 h post-dose (C 2 ) have been shown to be good predictors for the absorption profile [6] . Levy et al. [7] reported that a new monitoring strategy based on C 2 levels was superior to traditional C 0 monitoring for liver transplant recipients in terms of reducing the incidence and severity of acute rejections. The implementation of such a monitoring strategy requires that the relationship between the C 0 and AUC of tacrolimus be clarified in adult living-donor liver transplantation (LDLT) patients because the pharmacokinetics of tacrolimus during the early post-transplantation period may fluctuate widely according to the regeneration of the grafted liver [8, 9] .
The measurement of CN phosphatase activity in circulating blood is a pharmacodynamic approach for evaluating the immunosuppressive effect of CN inhibitors [10] . In an earlier study, we found that tacrolimus and cyclosporine had different inhibitory effects on CN activity in peripheral blood mononuclear cells (PBMCs) in de novo LDLT patients [11] . CN activity at trough time points represents a surrogate predictor for overall CN activity throughout the dosing intervals after cyclosporine administration in LDLT patients [12] . However, there is little information available on the relationship between overall CN activity throughout the dosing intervals and blood tacrolimus concentrations, and CN activity at trough time points, following the oral administration of tacrolimus in this population.
This study was designed to evaluate pharmacokinetic profiles in parallel with CN activity in PBMCs at 1 and 3 weeks after LDLT in adult patients. Our aim was to evaluate the relationship between blood tacrolimus concentration at each sampling time and drug exposure during the dosing intervals, as well as CN activity during the dosing intervals, to clarify the significance of monitoring tacrolimus trough blood concentration during the early post-transplantation phase.
Patients and methods

Study design
Patients older than 18 years who had undergone primary LDLT between November 2007 and February 2009 at the Department of Transplantation and Immunology, Kyoto University Hospital were included in this study. Patients who suffered from fulminant hepatitis or who were co-administered medications incompatible with tacrolimus were excluded. The study was discontinued when the administration of tacrolimus was stopped. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki as reflected in a priori approval by the Kyoto University Graduate School and the Faculty of Medicine Ethics Committee. Written informed consent was obtained from each patient.
Within 12 h after LDLT, we started immunosuppression therapy with a conventional tacrolimus formulation (Prograf; Astellas Pharma, Tokyo, Japan) and low-dose corticosteroids. The initial oral dose of tacrolimus was 0.05 mg/kg/day twice daily (0900 hours and 2100 hours), and the dose was adjusted to target blood tacrolimus concentrations according to the trough measurements during the 3 weeks following the transplantation surgery. The target C 0 was set between 10 and 15 ng/ml on postoperative days (PODs) 1-7, between 8 and 12 ng/ml on PODs 8-14, and between 6 and 10 ng/ml after POD 15, using a microparticle enzyme immunoassay (MEIA) method with an IMx analyzer (Abbott Japan Co., Tokyo, Japan). Corticosteroids were administered according to a protocol described previously [11] .
Blood samples (2 ml) were taken before and at 1, 2, 4, 8, and 12 h after the morning administration of tacrolimus on POD 6 or 8 (at 1 week) and POD 20 or 22 (at 3 weeks) in order to evaluate the effects of time after transplantation on the pharmacokinetics and pharmacodynamics of tacrolimus. The concentration of tacrolimus in whole blood was measured using three analytical procedures: highperformance liquid chromatography with tandem mass spectrometry (LC/MS/MS), as previously reported [13] ; the MEIA method; the enzyme-multiplied immunoassay instrument (EMIT) method, using the Viva-E System (Siemens Healthcare Diagnostics, Tokyo, Japan). Samples were assayed as soon as possible after blood collection, otherwise they were preserved at −20°C until the assay could be performed.
CN phosphatase activity in PBMCs was measured using the remainder of the blood sample after blood concentration measurements, as an index of the pharmacological effects of tacrolimus. The assay of CN phosphatase activity in PBMCs was performed usingγ-32 P-labeled regulatory subunit type II (RII) phosphopeptide as a substrate, according to a procedure described previously [11] . On the day of transplantation, a blood sample was obtained from each patient to determine the baseline CN activity (CN base ) before the administration of tacrolimus in that patient.
Pharmacokinetic and pharmacodynamic analysis
The AUC from 0 to 12 h (AUC 0-12 ) after tacrolimus administration was calculated according to the trapezoidal rule. The highest observed concentration and associated time point were defined as the maximum drug concentration (C max ) and the time at which the maximum concentration occurs (t max ), respectively. The apparent clearance (CL/F) was calculated by dividing the morning dose on each study day with the AUC 0-12 . The area under the CN activity-time curve from 0 to 12 h (AUA 0-12 ) after administration was also calculated according to the trapezoidal rule. The greatest observed CN inhibition, which caused a nadir of enzyme activity, and its associated time points were defined as the maximum CN inhibition (CN nadir ) and the corresponding time (t nadir ), respectively. The relationship between the blood tacrolimus concentration and CN activity in PBMCs was analyzed using the following maximum inhibitory effect (E max ) model:
where CN is the CN activity at blood concentration C; E max is the maximum inhibitory effect attributable to the drug, which is assumed to be the same as the baseline activity; EC 50 is the blood concentration that gives a half-maximal effect. The fixed parameters (θ) for E max and EC 50 were estimated by use of the nonlinear mixed effects modeling program NONMEM ver. 6.2 (ICON Development Solutions, Ellicott City, MD), and inter-individual variability (η) for E max and EC 50 , and residual variability (ε) were assumed to be log-normally distributed [11] .
Statistical analysis
Data are presented as the mean ± standard deviation (SD). Statistical analyses were performed using the statistical software package GraphPad Prism 5 (GraphPad Software, San Diego, CA). The statistical significance of differences in mean values between two groups was analyzed using the paired t test. Pearson's correlation coefficient (r) was used to estimate correlations between two factors. A value of P < 0.05 was considered to be statistically significant.
Results
Measurement of blood tacrolimus concentrations
We routinely measured blood tacrolimus concentrations by the MEIA method and compared these measurements and those obtained using the EMIT assay with LC/MS/MS data. Although the MEIA or EMIT measurements correlated with those obtained with the LC/MS/MS method, the r 2 values were relatively poor in the EMIT measurements (Fig. 1) . Consequently, we used the LC/MS/MS data subsequent analyses because it is the most reliable method and because the MEIA method using an IMx analyzer will not be commercially available until after 2010.
Pharmacokinetic and pharmacodynamic profiles of tacrolimus
Fourteen primary LDLT patients were enrolled in this study. The patients' demographic characteristics are summarized in Table 1 . Figure 2 shows the time-course profiles of the blood tacrolimus concentration and CN activity at 1 and 3 weeks after the LDLT. Table 2 shows the corresponding pharmacokinetic and pharmacodynamic parameters for tacrolimus. One patient had died due to infection by 3 weeks after the LDLT and therefore the data were not available for the time-course analysis. The blood concentration profile at 3 weeks after the LDLT changed gradually compared with that at 1 week, and the blood tacrolimus concentration at 1 h post-dose at 3 weeks posttransplantation was significantly lower than that at 1 week (Fig. 2a) . The AUC 0-12 was significantly smaller at 3 weeks than at 1 week after the LDLT (P<0.05), although the morning dose tended to increase from 0.020 at 1 week to 0.026 mg/kg at 3 weeks (Table 2) . Of the 13 patients for whom data were available at 3 weeks post-transplantation, 11 showed an increased CL/F compared with that at 1 week; this difference was statistically significant (Table 2 ; P<0.05). Thirteen patients would yield an 82% power to detect a 0.121 l/h/kg difference in CL/F (0.147 vs. 0.268 l/h/kg at 1 and 3 weeks, respectively) at a significance level of 0.05 (one-tailed test).
The CN activity changed slightly, and in parallel with the blood concentration, and returned to the pre-dose levels by 12 h post-dose at both 1 and 3 weeks after LDLT (Fig. 2b) . The CN activity at the trough time point (CN 0 ) was suppressed to approximately 65% of the baseline value at 1 week, and CN 0 activity at 1 and 3 weeks after LDLT was not statistically significantly different (Table 2 ; Fig. 2 ). Correlation between blood concentration and AUC of tacrolimus
The trough blood concentrations before the morning dose (C 0 ) and before the evening dose (C 12 ) were highly correlated with the AUC 0-12 ( Fig. 3 ; r 2 =0.767-0.888), although the correlation of C 0 at 1 week after LDLT was not so high (r 2 =0.530). The blood concentrations at 2, 4, and 8 h post-dose also showed strong correlations with the AUC 0-12 , but the correlation with the blood concentration at 1 h post-dose was weak (r 2 =0.411 or 0.498).
Relationship between blood concentration and CN activity
The CN activity in PBMCs was inhibited in a concentration-dependent manner by tacrolimus, but the inhibition was not complete even at blood tacrolimus concentrations of >20 ng/ml (Fig. 4) . (Fig. 5a, b) . The correlation between the AUA 0-12 and the AUC 0-12 was also poor (Fig. 5c) . However, the AUA 0-12 showed a strong correlation with CN 0 activity (r 2 =0.919 or 0.931; Fig. 5d ), as did CN activity at other time points (data not shown).
Discussion
Living-donor liver transplantation and subsequent immunosuppressive therapy provide excellent clinical results and are usually used in combination with a deceased donor organ-transplant program [14, 15] . Although the prevention of immunological reactions with sufficient immunosuppression prolongs graft and patient survival rates, the large inter-individual variation in tacrolimus pharmacokinetics interferes with the success of the treatment [16] . We previously reported that the probability of acute cellular rejection during the first 10 days after surgery was Fig. 3 Correlation between area under the concentration-time curve from 0 to 12 h (AUC 0-12 ) and tacrolimus blood concentration at pre-dose and 1, 2, 4, 8, and 12 h after the morning administration (C 0 , C 1 , C 2 , C 4 , C 8 , and C 12 , respectively). Each point represents the time-course data from 14 patients at 1 week (open circles) and from 13 patients at 3 weeks (closed circles) after LDLT. Solid and dashed lines Linear regression line at 1 and 3 weeks, respectively Fig. 4 Relationship between tacrolimus blood concentration and CN activity in LDLT patients. Each point shows time-course data from 14 patients at 1 week (open circles) and from 13 patients at 3 weeks (closed circles) after LDLT. Solid line Predicted calcineurin phosphatase activity versus the blood tacrolimus concentration profile according to the maximum inhibitory effect model as determined using the nonlinear mixed effects modeling program significantly associated with the average trough concentration of tacrolimus between PODs 2 and 4 [17] . However, we had no clear evidence from trough monitoring or AUC-based monitoring studies of the tacrolimus blood concentration. In this study, we confirmed that the trough tacrolimus blood concentration is a good surrogate marker for tacrolimus exposure during the dosing interval in LDLT patients.
In this time-course study, at 3 weeks after LDLT, the t max was prolonged and the difference between peak and trough concentrations was smaller compared with that at 1 week, indicating the delayed and poor absorption of tacrolimus at 3 weeks after LDLT (Fig. 2) . Although we cannot completely explain this phenomenon, the first-pass effects in the intestine and/or liver by cytochrome P450 3A and Pglycoprotein may be increased at 3 weeks after LDLT compared with 1 week. In addition, the apparent clearance of tacrolimus at 3 weeks after LDLT was approximately twice that at 1 week (Table 2 ). We previously reported that the total-body clearance of tacrolimus in LDLT patients increased with increasing number of POD because of the regeneration of grafted liver [8, 9] . According to the previously estimated population pharmacokinetic parameters [8] , a typical adult LDLT recipient in this study (grafted liver weight 611 g; normal hepatic and renal function; body weight of 67.1 kg during week 1 and 63.5 kg during week 3) would have a CL/F of 0.186 l/h/kg on POD 7 and 0.241 /h/kg on POD 21; these values are comparable to the mean CL/F in this study.
We also examined the correlation between AUC 0-12 and tacrolimus blood concentration at each sampling point (Fig. 3) . Although the correlation between the tacrolimus blood concentration at 1 h post-dose and the AUC 0-12 was weak, tacrolimus blood concentration at other time points showed reasonable or strong correlations with the AUC 0-12 .
Since the blood concentration at 12 h post-dose (C 12 ) will correlate with the AUC 0-12 for this dose and the C 0 should correlate with AUC 0-12 for the previous dose, it was expected that C 12 would show a higher correlation than C 0 . The relatively weak correlation found in C 0 at 1 week after LDLT was considered to be due to a large variability in the pharmacokinetics of tacrolimus immediately after LDLT, similar to earlier findings in renal transplant recipients [5] . A good correlation between AUC from 0 to 24 h and trough concentrations for both the twice-daily and once-daily prolonged tacrolimus formulations were reported in de novo kidney transplantation [18] . According to Scholten et al. [5] , Bayesian forecasting with a two-point sampling strategy, a trough level, and a second sample obtained between 2 and 4 h post-dose might improve the correlation with AUC 0-12 . Taking these finding into consideration, we concluded that a single-trough concentration before the morning dose is sufficient to provide an index of blood tacrolimus exposure during the dosing interval in LDLT patients, even during the early posttransplantation period.
The CN activity changed in parallel with the blood tacrolimus concentration and showed a similar flat time profile at 1 and 3 weeks after LDLT (Fig. 2) . These results indicate that, unlike cyclosporine [12] , tacrolimus partially suppressed CN activity throughout the dosing interval, probably because of the limited amount of active FK506-binding protein 12 in PBMCs [19] . The relationship between CN activity and tacrolimus blood concentration was analyzed using an E max model with an EC 50 of 20.9 ng/ml (Fig. 4) , which is higher than the upper limit of the therapeutic range of tacrolimus, as discussed in our previous report [11] . Additionally, Fig. 4 showed a large interindividual variability in the relation between tacrolimus exposure and CN activity. This phenomenon may be explained by the inter-individual variability of the expression level of P-glycoprotein in PBMCs [20] or variation in the PBMC subset concentrations [21] .
Further examination of the correlation between pharmacokinetic and pharmacodynamic parameters revealed that a single C 0 did not correlate with CN 0 or AUA 0-12 ( Fig. 5a, b) . In addition, as in our previous study of cyclosporine [12] , the AUC 0-12 of tacrolimus showed no relationship with AUA 0-12 (Fig. 5c) . These results indicate a large inter-individual variability in the relationship between tacrolimus blood exposure and CN activity; monitoring of only tacrolimus blood concentrations does not adequately maintain CN activity at a targeted level, as reported by Blanchet et al. [22] . However, CN 0 activity was strongly correlated with the AUA 0-12 ( Fig. 5d ; r 2 > 0.92). We recently reported that CN activity rapidly increased a few days before the onset of acute rejection in two patients after living-donor kidney transplantation [23] . Therefore, monitoring CN activity at the trough time point would be useful for predicting the overall CN activity in LDLT patients administered tacrolimus. In this study, we were unable to clarify the relationship between calcineurin activity and clinical outcomes, nor the therapeutic range of calcineurin activity. Consequently, the significance of the measurements of calcineurin activity remains to be clarified in a large cohort of liver transplant recipients.
In conclusion, we have shown that C 0 monitoring of tacrolimus can be used to evaluate drug exposure in LDLT patients during the early post-transplantation period and that the monitoring of CN activity at the trough time point could be useful for predicting the immunological status during the dosing interval of tacrolimus.
